The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic
peptide or a recombinant
protein comprising the antiangiogenic
peptide, wherein the
peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the
amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any
amino acid residue compatible with forming a
helix; X2 is an
amino acid residue of: Leu, Ile, Val; X3 is an
amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an
amino acid residue of: Ile, Leu, Val; X5 is any
amino acid residue compatible with forming a
helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a
helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.